|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.08.26 - 23:12
|
Merck & Co Aktie: Solides Q2 trotz Einmalbelastung (Aktiencheck)
|
|
|
Wien (www.aktiencheck.de) - Merck & Co-Aktienanalyse der Raiffeisen Bank International AG:
Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI), nimmt in einer aktuellen Aktienanalyse die Aktie von Merck & Co Inc. (ISIN: US58933Y1055, WKN: A0YD8Q, Ticker-Symbol: 6MK, NYSE-Symbol: MRK) unter die Lupe. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
|
04.08.26 - 14:57
|
AKTIONÄR-Top-Tipp Merck & Co: "King Keytruda" liefert – Aktie stark (Der Aktionaer)
|
|
|
Zahlreiche große Pharma-Konzerne legen in dieser Handelswoche ihre Zahlen zum abgelaufenen zweiten Quartal vor. Während am morgigen Mittwoch mit Eli Lilly und Novo Nordisk die Marktführer bei den Adipositas-Medikamenten ihre Bilanzen vorlegen, haben Pfizer und Merck & Co bereits am Dienstag frische Ergebnisse vorgelegt....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.08.26 - 12:36
|
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline (Business Wire)
|
|
|
Sales Growth Reflects Continued Strength in Oncology, Including Initial Uptake of KEYTRUDA QLEX, and Animal Health, Plus Contributions From Launches Such as WINREVAIR
Financial Highlights
Total Worldwide Sales Were $16.6 Billion (5% Growth; 4% Growth ex-FX)
KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.4 Billion (5% Growth; 4% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $463 Million
WINREVAIR Sales Were $588 Million (75% Growth; 75% Growth ex-FX)
Animal Health Sales Were $1.8 Billion (8% Growth; 5% Growth ex-FX)
GAAP Loss per Share Was $0.54; Non-GAAP Loss per Share Was $0.13; GAAP and Non-GAAP Loss per Share Include a Charge of $2.31 per Share for the Acquisition of Terns
Pipeline & Portfolio Highlights
Received U.S. FDA Approval for LIPFENDRA (enlicitide), the First and Only Once-Daily Oral PCSK9 Inhibitor To Reduce LDL-C in Adults With Hypercholesterolemia
Announced Positive Data From TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (sac-TMT) in Certain Patients With Advanced or Recurrent Endometrial Ca...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
